REMUS
Remus Pharmaceuticals Ltd
Each stock's 10,000-path forecast, rendered as light.
Remus Pharmaceuticals Ltd (REMUS) Stock Analysis & Case Study
What the numbers say about REMUS, and the method behind each one.
Remus Pharmaceuticals Ltd (REMUS) trades at ₹879,on the numbers it screens weak, a Downstox Snapshot Score of 36/100.
On the numbers, Remus Pharmaceuticals Ltd (REMUS) screens weak, a Downstox Snapshot Score of 36/100, weighing premium at 28.0× earnings, ROE of 12.2%, a 42% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
REMUS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How REMUS ranks against the 2,982 companies in our screener
- REMUS's market cap of 1,036 Cr ranks in the 50th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- REMUS's book value of ₹298 ranks in the 84th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- REMUS's promoter holding of 71.0% ranks in the 75th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- REMUS's 3-year profit (PAT) growth of 15.0% ranks in the 46th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- REMUS's 3-year revenue growth of 15.0% ranks in the 59th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- REMUS's debt-to-equity ratio of 0.08x is lower than 82% of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
Is REMUS overvalued? REMUS P/E vs peers
REMUS trades at 28.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
REMUS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 3.2y of REMUS history (23%/yr drift, 72%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| REMUS 2027 | ₹318 | ₹778 | ₹1,907 | -13% |
| REMUS 2028 | ₹187 | ₹675 | ₹2,441 | -25% |
| REMUS 2029 | ₹122 | ₹586 | ₹2,825 | -35% |
| REMUS 2030 | ₹80 | ₹508 | ₹3,220 | -43% |
| REMUS 2031 | ₹56 | ₹441 | ₹3,462 | -51% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability REMUS goes up, or doubles?
The bull case for REMUS
- REMUS's return on equity of 12.2% ranks in the 58th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,825.
The bear case & risks
- REMUS's P/E of 28.0x is lower than 44% of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- The probability model is cautious 12 months out, only a 42% chance of finishing above today's price.
- High historical volatility (72%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹122.
REMUS volatility & expected range, how bumpy is the ride?
Over the last 3.2 years REMUS compounded at 23%/year with annualized volatility of 72%. That volatility implies a 1-year 80% range of ₹318-₹1,907, the honest backbone behind any single price target.
REMUS price forecast, the full 60-month probability fan
REMUS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds REMUS hits common targets within the simulated horizon?
Full multi-horizon detail on the REMUS price target & forecast page.
REMUS Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. REMUS scores 6/8, mixed financial health.
About Remus Pharmaceuticals Ltd: sector, index & market-cap context
Remus Pharmaceuticals Ltd (REMUS) is a small-cap NSE-listed company, with a market capitalisation of ₹1,036 Cr. See more stocks on our screener.
How the REMUS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Remus Pharmaceuticals Ltd's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
REMUS analysis, FAQs
Is Remus Pharmaceuticals Ltd (REMUS) a good buy?
On the numbers, Remus Pharmaceuticals Ltd (REMUS) screens weak, a Downstox Snapshot Score of 36/100, weighing premium at 28.0× earnings, ROE of 12.2%, a 42% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is REMUS overvalued or undervalued?
REMUS trades at 28.0× earnings, premium versus the ~22× long-run Nifty average.
What is the REMUS share price target for 2031?
REMUS's probability-weighted 2031 median target is ₹441, with an 80% range of ₹56-₹3,462 (10,000-path Monte-Carlo).
What is the probability REMUS doubles in 5 years?
The modelled probability of REMUS reaching ₹1,795 (2×) within 5 years is 19%.
What is the bull case for REMUS?
REMUS's return on equity of 12.2% ranks in the 58th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
What are the risks in REMUS?
REMUS's P/E of 28.0x is lower than 44% of the 2,982 NSE companies in our screener, as of 14 Aug 2026. The probability model is cautious 12 months out, only a 42% chance of finishing above today's price. High historical volatility (72%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
More on REMUS
For information and education only. Downstox is a data and analytics platform, not a SEBI-registered Research Analyst or Investment Adviser. Nothing here is investment advice or a recommendation to buy, sell or hold any security. Any scores, ranks, targets or scenarios are model estimates shown with their method, not forecasts or assured outcomes. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing.